1243 results
Publication
Monthly information regarding the total number of voting rights and shares making of the share capital - August 2023
As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication
Buyback programs - August 2023 (french)
Monthly communication regarding buyback programs
Publication
2023 half-year Results
Sales: €256m (-5.4% as reported) Essentials products sales: €151m (59% of Group sales) Net income - Group share: €32m (12.6% of sales) EBITDA*: €54m (20.9% of sales) Cash-flow generation: €31m
Publication
2023 Half-Year Results
Contents 1.H1 2023 Highlights 2.H1 2023 Consolidatedfinancialstatements 3.Strategyand outlook
News
2024 half-year Results
Sales: € 264m (+3.2% as reported) Essential products sales: €160m (+6.0% as reported) Net income, Group share: €24m (9.0% of sales) EBITDA: €45m (17.0% of sales) Cash flow generation: €27m The Board of Directors of Vetoquinol SA met on September 10, 2024 to review business activity and approve the...
News
2023 half-year Results
Sales: €256m (-5.4% as reported) Essentials products sales: €151m (59% of Group sales) Net income - Group share: €32m (12.6% of sales) EBITDA*: €54m (20.9% of sales) Cash-flow generation: €31m Matthieu Frechin, Chairman and CEO of the Vetoquinol laboratory, commented: "In a global animal health...
Publication
Monthly information regarding the total number of voting rights - July 2023
As per articles L233‐8‐II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »
Publication
Mastaplex and Vetoquinol announce distribution agreement
Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..
Publication
Update July 11, 2023 2023 CALENDAR OF FINANCIAL COMMUNICATION
Update July 11, 2023 Vetoquinol published its calendar of financial communication for 2023.